Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (Nasdaq: NKTR) reported that 16-week induction data from the Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis were published in The Lancet. The global, randomized, double-blind, placebo-controlled study enrolled 393 biologic- and JAK inhibitor-naive adults across 107 sites in 10 countries.
All three dosing regimens met the primary endpoint, with mean EASI reductions at Week 16 of 61%, 58% and 53% versus 31% for placebo, and statistically significant key secondary endpoint improvements, including EASI-75, EASI-90, vIGA-AD 0/1, Itch NRS, and BSA for the 24 μg/kg q2w arm. Patient-reported outcomes such as DLQI, ADCT, pain, and sleep also improved versus placebo. Safety over 16 weeks showed 2% serious adverse events, no deaths, and no increased infection or conjunctivitis risk. Biomarker changes supported T-reg–mediated immunomodulation. These results underpin Nektar’s ongoing Phase 3 ZENITH AD program and broader development of rezpegaldesleukin, which has FDA Fast Track designations in moderate-to-severe atopic dermatitis and severe alopecia areata.
Nektar Therapeutics (Nasdaq: NKTR) reported second quarter 2026 revenue of $10.1 million, all from non-cash royalty revenue related to sales of future royalties, versus $11.2 million a year earlier. Net loss was $40.6 million (loss of $1.23 per share) compared with a $41.6 million loss ($2.95 per share) in Q2 2025.
Cash and investments in marketable securities rose to $1,023.4 million at June 30, 2026 from $245.8 million at December 31, 2025, helped by an April 2026 equity offering generating $373.8 million in gross proceeds. The company projects a cash runway into the third quarter of 2028.
R&D expense increased to $39.1 million in Q2, driven by initiation of Phase 3 ZENITH AD trials of rezpegaldesleukin in atopic dermatitis and related manufacturing. G&A expense decreased to $12.8 million, mainly from lower legal costs. Nektar also reported positive 52-week topline Phase 2b REZOLVE-AA data in severe alopecia areata.
Nektar Therapeutics (Nasdaq: NKTR) will announce financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S. financial markets. CEO Howard Robin will host a results conference call at 5:00 p.m. ET / 2:00 p.m. PT, accessible via live audio webcast and phone for pre-registered participants.
The webcast will be available on Nektar’s website and offered as a replay through September 13, 2026. Nektar is a clinical-stage biotech focused on autoimmune and chronic inflammatory diseases, led by its T-reg–stimulating candidate rezpegaldesleukin (REZPEG, NKTR-358) and additional preclinical programs.
Nektar Therapeutics (NASDAQ: NKTR) reported that on July 20, 2026, its Organization and Compensation Committee granted non-qualified stock options to purchase an aggregate of 36,000 shares of common stock to 23 newly hired employees under its 2025 Inducement Plan, adopted on November 6, 2025 and used solely for Nasdaq Listing Rule 5635(c)(4) inducement awards.
The options have an exercise price of $64.84, matching the July 20, 2026 closing price, an eight-year term, and vest over four years, subject to continued employment. Nektar is a clinical-stage biotechnology company whose lead candidate, rezpegaldesleukin (REZPEG, NKTR-358), is in a registrational program for atopic dermatitis and other immune-related indications.
Nektar Therapeutics (Nasdaq: NKTR) has begun the first two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, in its ZENITH AD program evaluating rezpegaldesleukin in patients aged 12+ with moderate-to-severe atopic dermatitis. Each of the three planned studies, including ZENITH AD-3 starting in September, will enroll about 510 patients, for a total of 1,530 patients worldwide.
The randomized, double-blind, placebo-controlled trials use 24 µg/kg rezpegaldesleukin every two weeks for 24 weeks, followed by a 28-week blinded maintenance phase with monthly or quarterly dosing. The Phase 3 design is based on a 393-patient Phase 2b study that showed clinically meaningful efficacy, favorable safety, and up to a five-fold increase in EASI-100 rates between Weeks 16 and 52. Primary registration endpoints focus on IGA 0/1 and EASI-75 at Week 24. Initial topline Phase 3 data are expected in mid-2028, with a targeted BLA submission in 2029.
Nektar Therapeutics (NASDAQ: NKTR) reported equity inducement grants made on June 19, 2026 under its 2025 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
The committee granted non-qualified stock options for 20,500 shares and 3,900 RSUs to seven new employees, with a $60.98 exercise price and four-year vesting schedules.
Nektar Therapeutics (NASDAQ:NKTR) reported inducement grants made on May 20, 2026 under its 2025 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The Board’s committee granted non-qualified options for 11,900 shares to five new employees at a $69.49 exercise price, with eight-year terms and four-year vesting.
Nektar Therapeutics (Nasdaq: NKTR) will participate in the 2026 Jefferies Global Healthcare Conference in New York. Management’s fireside chat is scheduled for Wednesday, June 3, 2026 at 1:20 p.m. ET and will be webcast live.
The webcast and 30-day replay will be accessible via Nektar’s investor events webpage.
Nektar Therapeutics (Nasdaq: NKTR) reported Q1 2026 results for the quarter ended March 31, 2026. Cash and marketable securities were $731.6 million at March 31, 2026, excluding approximately $351 million net proceeds from a secondary offering closed April 23, 2026. Revenue was $10.9 million. Total operating costs were $49.9 million; R&D expense was $35.7 million. Net loss was $44.9 million or $1.82 per share. Recent financings in February and April generated gross proceeds of $460 million and $373.8 million, respectively. Key upcoming milestones include Phase 3 ZENITH-AD initiation by July 2026 and an FDA End-of-Phase 2 meeting for alopecia areata in Q2 2026.
Nektar Therapeutics (NASDAQ:NKTR) announced inducement equity grants on April 20, 2026 under its 2025 Inducement Plan. The Organization and Compensation Committee granted non-qualified stock options for 28,450 shares and 2,950 RSUs to six newly hired employees.
Options have an $100.35 exercise price, eight-year term, and standard four-year vesting; RSUs vest over four years with quarterly vesting after year one.